UV Flu Technologies (UVFT.OB)
The FDA Approved Swine Flu Killer
Are you looking for a profitable penny stock pick? But you're sick and tired of investing in shady penny stock companies?
We were too. When thinking about investing in biotechnology or pharmaceutical penny stocks, there is always so much doubt and investors are never really sure about who they can trust.
We’re always looking for penny stock picks on the move and reputable companies with stories that can sell.
Lately, H1N1, Influenza A, Swine Flu---whatever you want to call it---is such a hot topic right NOW.
Why? In October, The White House declared H1N1 (Swine Flu) a national emergency and, more recently, the World Health Organization (WHO) reported that this global pandemic has killed more than 12,799 people.
In fact, Congress has set aside more than $10 billion this year to research flu viruses, monitor H1N1's progress and educate the public about prevention.
As a result, the U.S. government has seen an explosion in companies trying to profit on this swine flu frenzy by claiming their products are effective in fighting H1N1.
So what does this have to do with UVFT? EVERYTHING.
UV Flu Technologies (UVFT) is an FDA Approved Medical Device (U.S. Patent No. 6939397) and the stock is still trading under $0.50!
UVFT is committed to providing clean air to improve health and prevent the spread of disease. Its proven germicidal air purification technology removes and kills viruses, bacteria, mold and allergens with more than 99% efficiency.
Extensive independent testing by EPA and FDA certified laboratories confirms the proprietary system captures and kills airborne bacteria including Bacillus subtilis, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumonia and viruses including Influenza A and H1N1 at rates exceeding 99.2% on a first-pass basis. And the best part---
The company's UV 400 Viraguard is FDA Approved as a medical device.
What makes investing in UVFT different than other penny stock companies?
Innovative Technology & Quality Products
The company's flagship UV 400 ViraGuard product draws air in through a killing chamber cartridge where baffles provide the turbulence necessary to bring microbes in close proximity to the special UVC lamps, allowing the germicidal UV-C to kill any pathogens present. What does all this mean?
UVFT uses ultra violet technology to kill 99.2% of airborne germs and viruses including swine flu!
| MICROBE | Inactivation Rate | |||
|---|---|---|---|---|
| Pass 1 % | Pass 2 % | Pass 3 % | Pass 4 % | |
| SARS coronavirus | 34.2 | 56.67 | 81.23 | >99.99 |
| Adenovirus | 89.5 | 98.90 | 99.99 | >99.99 |
| Influenza A (H1N1) | 99.2 | >99.99 | >99.99 | >99.99 |
| Bacillus subtilis | 99.7 | >99.99 | >99.99 | >99.99 |
| Variola (smallpox) | 99.8 | >99.99 | >99.99 | >99.99 |
Independent EPA and FDA certified laboratory testing confirms the system captures and kills airborne bacteria including Bacillus subtilis, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumonia and viruses including Influenza A and H1N1 at rates ranging from 99.2% to more than 99.99% on a first-pass basis. In actual operation multiple passes through the unit will occur, producing average removal rates that far exceed 99.2%.
Reasons why UVFT may trade between $5-10 in the near future:
- FDA approval (U.S. Patent No. 6939397) to market the UV Flu system as a medical device.
- Independent lab testing confirming over 99% effectiveness in eliminating viruses, bacteria, mold and allergens
- Environmentally friendly, energy conscious technology (uses less energy than a 100-watt light bulb and can qualify for Green Building programs)
- Third party testing and certification of product as electrically and operationally safe to use (eliminating product liability issues)
- Unique replaceable cartridge design to provide continuous revenue stream throughout life of product
Is there a market for UVFT's product? Yes!
Increased media attention and growing public concern over the rise of the H1N1 swine flu pandemic, antibiotic resistant superbugs, asthma, allergies, tuberculosis, Sick Building Syndrome and toxic mold are spurring governments, employers and homeowners to take action to safeguard their health. In fact, there's a rising demand for indoor air quality (IAQ) technology!
According to BCC Research's global analysis of the global air purification equipment market and the U.S. indoor air quality (IAQ) market:
The market for air purification equipment has been gaining momentum as a result of rising concerns over IAQ and increasing health consciousness among consumers.
The IAQ market generated $7.7 billion in 2008, with the equipment sector of the market accounting for $3.6 billion. (see above).
Continuing media attention given to the health effects of toxic mold, the outbreak of infectious diseases such as swine flu, and the increase in chronic respiratory diseases such as asthma have resulted in new interest in, and attention to, indoor air quality.
SOURCE: BCC Research, "U.S. Indoor Air Quality Market", August 2009
This means that UVFT has the potential to not only relieve national health concerns and increase business productivity but could also benefit smart investors like you who do their homework:
- The indoor air quality (IAQ) equipment market was valued at $3.6 billion in 2005 and is expected to reach $10.4 billion by 2011, a 5.2% average annual growth rate (AAGR) over the next 5-year period.
- Consulting and testing services were valued at $1.5 billion in 2005 and should reach $2.7 billion by 2011 based on a 10% AAGR over the next 5-year period. Environmental services, including mold remediation, asbestos abatement, and radon mitigation, were valued at $1.6 billion in 2005 and, based on an AAGR of 9.5%, should reach $2.9 billion by 2011.
- Currently, the end-use markets with the biggest potential for applications of IAQ equipment and services include residential dwellings, commercial buildings, schools, and health care facilities. The commercial segment was the largest market for IAQ equipment and services, accounting for 26% of the market in 2005, followed by schools (22%), residences (19%), and health care facilities (17%).
- The Center for Disease Control and Prevention (CDC) reports 23.4 million Americans have asthma and The Asthma and Allergy Foundation of America estimates that 1 in 5 Americans suffers from allergies.
After reading this, you can see that UVFT is a real company with a real product, and that's why we're tremendously excited about UVFT as an investment opportunity.
UVFT is currently trading under $0.50, has an FDA approved medical device, a sexy story that can sell, and the potential to be worth 10 to 20 times as much---
That’s a $5 to $10 stock and the type of penny stock profits you've been looking for.
Contact An Investment Professional About UVFT Today and Look Forward to a Profitable and Healthier Future For You and Your Loved Ones. Don’t wait for this lucrative opportunity to benefit from the swine flu frenzy pass you by, ACT NOW!
Join the UVFT Email Alert List Today to stay current with all UVFT developments.